Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to maraviroc + darunavir/ritonavir once daily versus continuation of current triple antiretroviral therapy in virologically suppressed HIV infection
2010-023316-13Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of maraviroc, darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Virological failure at 48 weeks. Started Dec 2010; status: completed.
02
Drugs
maravirocdarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-023316-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023316-13.